Videos

Sam S. Chang, MD, MBA, highlights 2 studies presented at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco, California, that he believes are particularly impactful for clinicians treating bladder cancer.

The discussion explores how the rising burden of comorbidities and polypharmacy in patients with metastatic castration-sensitive prostate cancer requires clinicians to carefully balance therapy intensification with overall health status, medication interactions, and long-term safety when developing individualized treatment plans.

The discussion introduces how the treatment landscape for metastatic castration-sensitive prostate cancer has evolved, highlighting that patients are now living longer with metastatic disease and often have multiple comorbidities, making long-term tolerability and quality of life key considerations in treatment planning.

Dinesh Singh, MD, emphasizes that radiation reduction begins at the diagnostic stage, favoring low-dose CT scans over standard-dose imaging.

Mustafa J. Saleh, MD, highlights new research exploring whether germline-based polygenic risk scores could help predict outcomes for patients with kidney cancer.

In this video, Gordon A. Brown, DO, FACOS, discusses PTEN deficiency as a prognostic marker and its implications for treatment selection, monitoring, and risk stratification in mHSPC.

Discover essential strategies for managing advanced prostate cancer, including team collaboration, systematic documentation, and patient care best practices.

On Hugo's modular arm architecture, Porter contrasts it with the traditional "boom" design that has dominated robotic surgery for over 2 decades.

Maha H. A. Hussain, MD, FASCO, FACP, outlines the design and key findings from a phase 2 trial of abiraterone plus olaparib vs each agent alone in mCRPC.

Telemedicine has also expanded access, allowing patients to choose either virtual or in-person visits. However, Kaylani Narra, MD, emphasized that limited genetic counseling capacity remains a major barrier.

According to Sophia Kamran, MD, innovation in bladder cancer is expanding treatment options and patient-centered care.

Vignesh T. Packiam, MD, reviews several bladder cancer studies from ASCO GU 2026 that he described as clinically meaningful for practicing urologists.

Rubenstein emphasizes the importance of strong clinical documentation and preparation by billing teams.

Laura Bukavina, MD, MPH, MSc, sat down to discuss the emerging role of ctDNA in guiding treatment decisions for patients with muscle-invasive bladder cancer, drawing on findings from the RETAIN and RETAIN 2 trials.

For asymptomatic renal stones, Mathew D. Sorensen, MD, MS, FACS, said he believes Break Wave could meaningfully influence the long-standing debate between surveillance and early intervention.

Chad Tang, MD, discusses the development of a prognostic model—K-COMPASS—for patients with oligometastatic clear cell renal cell carcinoma.

Health care professionals discuss the growing preference for oral hormone therapy over injectables, emphasizing patient control and comfort in treatment choices.

Experts discuss the cardiovascular risks associated with androgen deprivation therapy, comparing relugolix and leuprolide's impact on coronary plaque formation.

Gordon A. Brown, DO, FACOS, gives an overview of PTEN biology, distinctions between PTEN loss and deficiency, and the clinical importance of PI3K/AKT pathway activation in prostate cancer progression.

Robert S. Svatek, MD, discusses the background and key findings from the SWOG S1602 trial, evaluating BCG strain differences and intradermal BCG before intravesical therapy for patients with BCG-naïve NMIBC.

Sophia C. Kamran, MD, highlights some of the key bladder cancer trials presented at ASCO GU 2026 from the perspective of a radiation oncologist.

According to Alex Tatem, MD, misinformation online and aggressive marketing frequently push patients toward unregulated providers offering injectable silicone or other non-medical substances.

A permanent J code helps standardize billing and clarifies expected payment levels, often embedding reimbursement terms into payer contracts.

Matthew D. Galsky, MD, discusses what is needed for successful integration of BCG/ICI combinations in BCG-naive non–muscle invasive bladder cancer.

Kristen R. Scarpato, MD, MPH, discusses the potential role of emerging immunotherapy-based combinations in the treatment of BCG-naive, high-risk non–muscle invasive bladder cancer.

As immunotherapy and antibody-drug conjugates move earlier in treatment, questions about sequencing therapies are emerging.

Toni K. Choueiri, MD, discusses the background and key findings from the phase 3 LITESPARK-022 trial.

David R. Wise, MD, PhD, highlights initial findings from a phase 1b study of pasritamig plus docetaxel in patients with metastatic castration-resistant prostate cancer.

Fred Saad, MD, FRCP, highlights the background and key findings from the phase 1 PAnTHa study.

Pooja Ghatalia, MD, shares data from an integrated analysis of the RETAIN trials in muscle-invasive bladder cancer.